Evidence map›Paper›PMID 31327842›Full record

ArticleInternal medicine (Tokyo, Japan)2019

Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.

Miki Yamazaki, Chiaki Nakaseko, Masahiro Takeuchi, Shinichi Ozawa, Yasuhiro Ishizuka, Yasuhito Hatanaka, Nagisa Oshima-Hasegawa, Tomoya Muto, Shokichi Tsukamoto, Shio Mitsukawa and 6 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Miki YamazakiDepartment of Hematology, Chiba University Hospital, Japan.
Chiaki NakasekoDepartment of Hematology, Chiba University Hospital, Japan.
Masahiro TakeuchiDepartment of Hematology, Chiba University Hospital, Japan.
Shinichi OzawaDepartment of Hematology, JCHO Funabashi Central Hospital, Japan.
Yasuhiro IshizukaDepartment of Hematology, JCHO Funabashi Central Hospital, Japan.
Yasuhito HatanakaDepartment of Hematology, Chiba University Hospital, Japan.
Nagisa Oshima-HasegawaDepartment of Hematology, Chiba University Hospital, Japan.
Tomoya MutoDepartment of Hematology, Chiba University Hospital, Japan.
Shokichi TsukamotoDepartment of Hematology, Chiba University Hospital, Japan.
Shio MitsukawaDepartment of Hematology, Chiba University Hospital, Japan.
Chikako OhwadaDepartment of Hematology, Chiba University Hospital, Japan.
Yusuke TakedaDepartment of Hematology, Chiba University Hospital, Japan.
Naoya MimuraDepartment of Hematology, Chiba University Hospital, Japan.
Tohru IsekiDepartment of Hematology, Chiba University Hospital, Japan.
Motoharu FukazawaDepartment of Hematology, JCHO Funabashi Central Hospital, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Japan.
Chiba University Hospital · JPFunabashi Central Hospital · JPInternational University of Health and Welfare · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid/lymphoid neoplasms with PDGFRB rearrangement are a distinct type of myeloid neoplasms that occur in association with rearrangement of PDGFRB at 5q32. The hematological features most often show prominent eosinophilia. We herein report a patient with myeloid/lymphoid neoplasms with PDGFRB rearrangement with t (5;10) (q33;q22) who showed atypical chronic myeloid leukemia-like clinical features without eosinophilia and achieved an optimal response to imatinib. A sequence analysis showed a CCDC6-PDGFRB fusion gene with a new break point in the PDGFRB gene. This is the sixth case of myeloid/lymphoid neoplasm with PDGFRB rearrangement harboring a CCDC6-PDGFRB fusion gene, and it has a new breakpoint in the PDGFRB fusion gene.

Indexed as

Antineoplastic AgentsCytoskeletal ProteinsEosinophiliaGene RearrangementHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedOncogene Proteins, FusionReceptor, Platelet-Derived Growth Factor betaTranslocation, GeneticAntineoplastic AgentsCCDC6 protein, humanCytoskeletal ProteinsImatinib MesylateOncogene Proteins, FusionPDGFRB protein, humanReceptor, Platelet-Derived Growth Factor betaatypical chronic myeloid leukemiaCCDC6-PDGFRBimatinibmyeloid/lymphoid neoplasms with PDGFRB rearrangementt (5;10) (q33;q22)

Identifiers

PMID31327842
PMCPMC6928497
OpenAlexW2963081140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.